Manitimus

Research use only, not for human use.

Manitimus (FK778) is an inhibitor of dehydroorotate dehydrogenase and an immunosuppressant with immunosuppressive and antiproliferative activity.

Manitimus is an inhibitor of dehydroorotate dehydrogenase, and a potent immunosuppressive agent. Manitimus is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

——

In the Manitimus-treated rats, there is a dose-related, differential effect: mean survival is 15.7 days in group 4 (Manitimus 5 mg/kg), 19.1 days in group 5 (Manitimus 10 mg/kg) and 25.4 days in group 6 (Manitimus 20 mg/kg). Manitimus (15 mg/kg, p.o.) results in a significant decrease in neointimal area and percentage of stenosis versus the control rats, and diminishes the effect that CMV infection results in a significant increase in intimal and medial cross-sectional area and medial wall thickness of the vein grafts.

——

Metabolic Enzyme/Protease

Dehydrogenase

Dehydrogenase

——

——

202057-76-9

308.26

C15H11F3N2O2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (811.00 mM; Ultrasonic )

C(\C(NC1=CC=C(C(F)(F)F)C=C1)=O)(=C(/CCC#C)\O)/C#N

——

(-20℃)

With Ice Pack

≥ 2 years